Patient Rating:

No Rating Available?

Kamisha L. Johnson-Davis, Ph.D.

Patient Rating:

No Rating Available?

Specialties

  • Pathology, Clinical

Languages

  • English

Clinical Details

Phone Number Clinical Office Address

Specialties

  • Pathology, Clinical

Bio

Dr. Johnson-Davis is an Assistant Professor at the University of Utah in the Department of Pathology and the Medical Director for the Clinical Toxicology Lab II and immunosuppressant testing at ARUP Laboratories. Dr. Johnson-Davis is board certified in Clinical Chemistry and is a Diplomate of the American Board of Clinical Chemistry and a Fellow of the National Association of Clinical Biochemistry.

Board Certification and Academic Information

Academic Departments Pathology - Assistant Professor (Clinical)
Pharmacology and Toxicology - Adjunct Assistant Professor
Academic Divisions Clinical Pathology
Board Certification American Board of Clinical Chemistry (Sub: Clinical Chemistry)
American Board of Clinical Chemistry (Sub: Toxicological Chemistry)

Academic Profile

Board Certification and Academic Information

Academic Departments Pathology - Assistant Professor (Clinical)
Pharmacology and Toxicology - Adjunct Assistant Professor
Academic Divisions Clinical Pathology
Board Certification American Board of Clinical Chemistry (Sub: Clinical Chemistry)
American Board of Clinical Chemistry (Sub: Toxicological Chemistry)

Academic Office Locations

Academic Office Phone Number Academic Office Address
ARUP
ARUP Laboratories
500 Chipeta Way
Salt Lake City, UT 84108

Academic Bio

Dr. Johnson-Davis received her B.S. degree in Biochemistry from the University of California, Riverside and her Ph.D. in pharmacology at the University of Utah. She completed her postdoctoral fellowship in clinical chemistry at the University of Utah, Department of Pathology, and was a postdoctoral research associate at the Center of Human Toxicology at the University of Utah.

Education

Education History

Type School Degree
Fellowship University of Utah, Department of Pathology
Clinical Chemistry
Fellow
Postdoctoral Fellowship University of Utah, Center for Human Toxicology, Research Associate
Human Toxicology
Postdoctoral Fellow
Doctoral Training University of Utah, Department of Pharmacology &Toxicology
Pharmacology
Ph.D.
Undergraduate University of California, Riverside, Department of Biochemistry
Biochemistry
B.S.

Publications

Selected Provider Publications

Journal Article

  1. Rule GS, Rockwood AL, Johnson-Davis KL (2014). An LC/MS/MS method for determination of Teriflunomide, over a 40,000 fold dynamic range using overlapping calibrators. (Epub ahead of print) Ther Drug Monit.
  2. Marin SJ, Sawyer JC, He X, Johnson-Davis KL (2014). Comparison of Drug Detection by Three Quadrupole Time-of-Flight Mass Spectrometry Platforms.LID - bku134 [pii]. (Epub ahead of print) J Anal Toxicol.
  3. Petrides AK, Moskowitz J, Johnson-Davis KL, Jannetto PJ, Langman LJ, Clarke W, Marzinke MA (2014). The development and validation of a turbulent flow-liquid chromatography-tandem mass spectrometric method for the simultaneous quantification of citalopram, sertraline, bupropion and hydroxybupropion in serum. Clin Biochem, 47(15), 73-9.
  4. Lin CN, Juenke JM, Johnson-Davis KL (2014). Method validation of a tricyclic antidepressant drug panel in urine by UPLC-MS/MS. Ann Clin Lab Sci, 44(4), 431-6.
  5. McMillin GA, Slawson MH, Marin SJ, Johnson-Davis KL (2013). Demystifying analytical approaches for urine drug testing to evaluate medication adherence in chronic pain management. J Pain Palliat Care Pharmacother, 27(4), 322-39.
  6. Johnson-Davis KL, Thompson CD, Clark CJ, McMillin GA, Lehman CM (2012). Method comparison of the Ortho Vitros Fusion 5,1 chemistry analyzer and the Roche COBAS Integra 400 for urine drug screen testing in the emergency department. J Anal Toxicol, 36(5), 345-8.
  7. McMillin GA, Johnson-Davis K, Dasgupta A (2012). Analytical performance of a new liquid chromatography/tandem mass spectrometric method for determination of everolimus concentrations in whole blood. Ther Drug Monit, 34(2), 222-6.
  8. Juenke JM, Miller KA, Ford MA, McMillin GA, Johnson-Davis KL (2011). A comparison of two FDA approved lamotrigine immunoassays with ultra-high performance liquid chromatography tandem mass spectrometry. Clin Chim Acta, 412(19-20), 1879-82.
  9. Johnson-Davis KL, Fernelius C, Eliason NB, Wilson A, Beddhu S, Roberts WL (2011). Blood enzymes and oxidative stress in chronic kidney disease: a cross sectional study. Ann Clin Lab Sci, 41(4), 331-9.
  10. Juenke JM, Wienhoff KA, Anderson BL, McMillin GA, Johnson-Davis KL (2011). Performance characteristics of the ARK diagnostics gabapentin immunoassay. Ther Drug Monit, 33(4), 398-401.
  11. Johnson-Davis KL, De S, Jimenez E, McMillin GA, De BK (2011). Evaluation of the Abbott ARCHITECT i2000 sirolimus assay and comparison with the Abbott IMx sirolimus assay and an established liquid chromatography-tandem mass spectrometry method. Ther Drug Monit, 33(4), 453-9.
  12. Juenke JM, Miller KA, McMillin GA, Johnson-Davis KL (2011). An automated method for supporting busulfan therapeutic drug monitoring. Ther Drug Monit, 33(3), 315-20.
  13. Juenke JM, Brown PI, Johnson-Davis KL, McMillin GA (2011). Simultaneous quantification of levetiracetam and gabapentin in plasma by ultra-pressure liquid chromatography coupled with tandem mass spectrometry detection. Ther Drug Monit, 33(2), 209-13.
  14. Johnson-Davis KL, Moore SJ, Owen WE, Cutler JM, Frank EL (2009). A rapid HPLC method used to establish pediatric reference intervals for vitamins A and E. Clin Chim Acta, 405, 35-38.
  15. Danaceau JP, Deering CE, Day JE, Smeal SJ, Johnson-Davis KL, Fleckenstein AE, Wilkins DG (2007). Persistence of tolerance to methamphetamine-induced monoaminergic deficits. Eur J Pharmacol, 559(1), 46-54.
  16. Rau KS, Birdsall E, Hanson JE, Johnson-Davis KL, Carroll FI, Wilkins DG, Gibb JW, Hanson GR, Fleckenstein AE (2005). Bupropion increases striatal vesicular monoamine transport. Neuropharmacology, 49(6), 820-30.
  17. Truong JG, Wilkins DG, Baudys J, Crouch DJ, Johnson-Davis KL, Gibb JW, Hanson GR, Fleckenstein AE (2005). Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity. J Pharmacol Exp Ther, 314(3), 1087-1092.
  18. Johnson-Davis KL, Truong JG, Fleckenstein AE, Wilkins DG (2004). Alterations in vesicular dopamine uptake contribute to tolerance o the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther, 309(2), 578-586.
  19. Johnson-Davis KL, Fleckenstein AE, Wilkins DG (2003). The role of hyperthermia and metabolism as mechanisms of tolerance to methamphetamine neurotoxicity. Eur J Pharmacol, 482(1-3), 151-4.
  20. Johnson-Davis KL, Hanson GR, Keefe KA (2003). Lack of effect of k-opioid receptor agonism on long-term methamphetamine-induced neurotoxicity in rats. Neurotox Res, 5(4), 273-282.
  21. Johnson-Davis KL, Hanson GR, Keefe KA (2002). Long-term post-synaptic consequences of methamphetamine on preprotachykinin mRNA expression. J Neurochem, 82(6), 1472-1479.

Clinical Trials

Video & News